Anti-Human ARG2 (Clone CPTC-ARG2-1) – Purified No Carrier Protein

Synthetic peptide TFDLLIGK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0122C-1F5-H1/K1 activity is directed against human arginase, type II (ARG2) peptide sequence TFDLLIGK.

CPTC-ARG2-1

Arginase, type II (arginase 2; ARG2) is a manganese metalloenzyme that catalyzes the hydrolysis of L-arginine¹. Arginine is a semi-essential amino acid used for protein biosynthesis that is critical for tissue repair, cell viability, and immune function. ARG2 is positively regulated by IL-10, an anti-inflammatory cytokine². Dysregulation of ARG2 expression in the tumor microenvironment allows for evasion from the host immune surveillance system¹. Increased ARG2 promotes the immunosuppressive environment by depleting local L-arginine levels. T cells are auxotrophic for L-arginine, and the reduction in extracellular arginine negatively impacts T cell proliferation and leads to suppression of anti-tumor T-cell-mediated immune responses. Additionally, the reduction in circulating arginine skews the monocytic populations to an immunosuppressive phenotype. ARG2 blockade is being investigated for the restoration of T cell proliferation and tumor suppression activity.

EB0122C-1F5-H1/K1 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human ARG2, TFDLLIGK³. EB0122C-1F5-H1/K1 does not detect ARG2 by immunohistochemistry, immunofluorescence, reverse phase protein array, or as recombinant protein by Western blotting⁴. EB0122C-1F5-H1/K1 does detect ARG2 in Western blots of buffy coat, HeLa, Jurkat, A549, MCF7, and H226 whole cell lysates.

https://antibodies.cancer.gov/detail/CPTC-ARG2-1#CPTC-ARG2-1

Arginase, type II (ARG2) localizes to the mitochondria and is expressed most abundantly in kidney and prostate tissues and then much less abundantly in brain, small intestine, heart, skeletal muscle, and placental tissues. ARG2 is also expressed in cells of monocytic lineages (e.g. inflammatory macrophages), endothelial cells, airway epithelial cells, activated T cells, and fetal dendritic cells.

Manganese

1 Austin M, Burschowsky D, Chan DTY, et al. MAbs. 12(1):1801230. 2020.
2 Dowling JK, Afzal R, Gearing LJ, et al. Nat Commun. 12(1):1460. 2021.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-ARG2-1#CPTC-ARG2-1